Our client required a comprehensive strategic plan for Biotech that demonstrated with robust evidence the health and economic value of the sector in Europe.
CRA carried out an interview program to collect the perspectives of stakeholders and policy makers in Brussels on the challenges facing the biotech sector. The program documented the health and economic value of the sector for Europe using the latest evidence and articulated the relationship between the biotech value story and the policy environment.
The project provided the client with evidence that the healthcare biotech industry adds value in two quite distinct ways. First, it creates preventive and therapeutic solutions to combat serious diseases; and, second, it is a high technology innovative industry, which competes effectively in world markets, creating employment and wealth and supporting economic growth in Europe.